Ventyx Biosciences stock drops as colitis drug trial falls short of expectationsProactive Investors • 10/10/23
Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative ColitisGlobeNewsWire • 10/09/23
Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate ProgressGlobeNewsWire • 08/10/23
Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth ConferenceGlobeNewsWire • 08/02/23
Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 InhibitorGlobeNewsWire • 06/14/23
Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque PsoriasisGlobeNewsWire • 06/07/23
Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate ProgressGlobeNewsWire • 05/11/23
Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023GlobeNewsWire • 05/04/23
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech NamesBenzinga • 04/20/23
Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual ConferenceGlobeNewsWire • 03/24/23
Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate ProgressGlobeNewsWire • 03/23/23
Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023GlobeNewsWire • 03/15/23
Recent Price Trend in Ventyx Biosciences, Inc. (VTYX) is Your Friend, Here's WhyZacks Investment Research • 02/27/23
Wall Street Analysts See a 26.67% Upside in Ventyx Biosciences, Inc. (VTYX): Can the Stock Really Move This High?Zacks Investment Research • 02/13/23
Ventyx Biosciences, Inc. (VTYX) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 02/10/23
Are You Looking for a Top Momentum Pick? Why Ventyx Biosciences, Inc. (VTYX) is a Great ChoiceZacks Investment Research • 02/03/23
Wall Street Analysts Think Ventyx Biosciences, Inc. (VTYX) Could Surge 38.99%: Read This Before Placing a BetZacks Investment Research • 01/26/23
Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D DayGlobeNewsWire • 01/26/23